Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $44.75, but opened at $42.11. Zealand Pharma A/S shares last traded at $42.11, with a volume of 110 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZLDPF. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The firm has a 50 day moving average of $47.67 and a 200-day moving average of $55.51. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.01 billion, a P/E ratio of 3.12 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The business had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. On average, equities research analysts predict that Zealand Pharma A/S will post 2.37 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.